分子诊断技术和靶向治疗在乳腺癌个体化治疗中的应用(4)
[13] Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer[J]. Oncoloqist, 2005, 10(9): 665-685.
[14] Perez EA. Paclitaxel in breast cancer[J]. Oncoloqist, 1998, 3(6): 373-389.
[15] Jones SE. Metastatic breast cancer: the treatment challenge[J]. Clin Breast Cancer, 2008, 8(3): 224-233.
[16] Gralow J, Ruqo H, Gradishar W, et al. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus round table[J]. Clin Breast Cancer, 2008, 8(1): 33-37.
[17] Burgess DJ, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo[J]. Proc Natl Acad Sci USA, 2008, 105(26): 9053-9058.
[18] Sève P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?[J]. Lancet Oncol, 2008, 9(2): 168-175.
[19] Arai T, Miyoshi Y, Kim SJ, et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers[J]. Eur J Surq Oncol, 2008, 34(7): 734-738.
[20] Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy[J]. Neoplasia, 2010, 12(8): 628-636., 百拇医药(汪洁)
[14] Perez EA. Paclitaxel in breast cancer[J]. Oncoloqist, 1998, 3(6): 373-389.
[15] Jones SE. Metastatic breast cancer: the treatment challenge[J]. Clin Breast Cancer, 2008, 8(3): 224-233.
[16] Gralow J, Ruqo H, Gradishar W, et al. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus round table[J]. Clin Breast Cancer, 2008, 8(1): 33-37.
[17] Burgess DJ, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo[J]. Proc Natl Acad Sci USA, 2008, 105(26): 9053-9058.
[18] Sève P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?[J]. Lancet Oncol, 2008, 9(2): 168-175.
[19] Arai T, Miyoshi Y, Kim SJ, et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers[J]. Eur J Surq Oncol, 2008, 34(7): 734-738.
[20] Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy[J]. Neoplasia, 2010, 12(8): 628-636., 百拇医药(汪洁)